TIDMOXB

RNS Number : 6631O

Oxford Biomedica PLC

22 August 2017

Director Dealings / Market Share Sale and Purchase

Oxford, UK - 22 August 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 21 August 2017 Tim Watts, Chief Financial Officer, exercised options over 8,244,169 ordinary shares of 1p each ("Ordinary Shares") in the Company. The options were exercisable at a cost of 1p per share and Mr Watts has sold 965,374 shares at 8.6p in order to fund the GBP82,442 cost of exercise. These options were granted in 2012, 2013 and 2014 under the Company's 2007 Long Term Incentive Plan.

Following the exercise Mr Watts holds 15,998,954 ordinary shares of 1p each ("Ordinary Shares") in the Company, 0.52% of the Company's issued share capital.

The issued share capital of the Company is 3,103,516,399 1p ordinary shares.

-Ends-

 
 For further information, 
  please contact: 
  Oxford BioMedica plc:                     Tel: +44 (0)1865 
   John Dawson, Chief Executive              783 000 
   Officer 
   Tim Watts, Chief Financial 
   Officer 
  Financial and corporate communications    Tel: +44 (0)20 3709 
   enquiries:                                5700 
   Consilium Strategic Communications 
   Mary-Jane Elliott/Matthew 
   Neal/Philippa Gardner/Laura 
   Thornton

Notes for editors

About Oxford BioMedica(R)

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCPTMLTMBJTMJR

(END) Dow Jones Newswires

August 22, 2017 05:35 ET (09:35 GMT)

Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to May 2024 Click Here for more Oxford Biomedica Charts.
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Oxford Biomedica Charts.